The weight loss drug Ozempic, containing semaglutide from the group of GLP-1 drugs, reduces the risk of depression, anxiety and addiction along with weight loss. A large-scale study found significant reductions in depression, anxiety and visits to psychiatric hospitals among users. Substance use disorders were significantly lower during treatment. GLP-1 hormone drugs reduced the risk of psychotic disorders by 18 percent, Alzheimer's disease by 12 percent, and addictive disorders by an average of 13 percent. These drugs work on areas of the brain involved in reward and impulse control, reducing cravings for tobacco, alcohol, cannabis, and opiates. Scientists hypothesize the impact of lifestyle improvements and direct effects on the brain.[5]